
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is facing constrained near-term visibility and elevated execution risk, leading to a lowering of our rating from Buy to Hold due to limited catalysts and tightening capital resources. While the company has made progress in advancing GEO-MVA and strengthening its intellectual property, the recent $1M registered direct offering highlights potential funding constraints and increases the likelihood of additional dilutive capital raises for the company to advance its pipeline.
Bears say
Geovax Labs is a clinical-stage biotechnology company with a negative outlook, due to the company's high reliance on its GEO-MVA platform, which is in its early stages with no approved products. In addition, the recent reverse stock split and low cash balance increase the risk of future dilution for investors. The company reported a decline in revenue and a net loss in 2025, highlighting its financial challenges and the need for external funding. While there are potential catalysts in the form of clinical progress and new studies, they are unlikely to impact the company's valuation in the near term, leading to a negative outlook.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares